55 related articles for article (PubMed ID: 38617837)
1. Delamanid and bedaquiline resistance patterns in
Akbari Aghababa A; Nasiri MJ; Pakzad P; Mirsamadi ES
New Microbes New Infect; 2024; 60-61():101437. PubMed ID: 38873345
[TBL] [Abstract][Full Text] [Related]
2. Effect of delamanid on interim outcomes of bacteriological conversion amongst pediatric drug resistant tuberculosis cases in India.
Kalawadia D; Gandhi D; Dirkhipa TY; Jaiswal A; Shah D; Salve J; Parmar M; Sachdeva KS; Bodhanwala M; Shah I
Lung India; 2024 Jan; 41(1):35-39. PubMed ID: 38160457
[TBL] [Abstract][Full Text] [Related]
3. Safety and effectiveness of three novel all-oral shortened regimens for rifampicin- or multidrug-resistant tuberculosis in Kazakhstan.
Rashitov M; Franke M; Trevisi L; Bekbolatova G; Shalimova J; Eshmetov G; Bektasov S; LaHood A; Arlyapova N; Osso E; Yedilbayev A; Korotych O; Ciobanu A; Skrahina A; Mitnick CD; Seung K; Algozhin Y; Rich ML
Clin Infect Dis; 2024 Jun; ():. PubMed ID: 38833593
[TBL] [Abstract][Full Text] [Related]
4. Whole Genome Sequencing for the Analysis of Drug Resistant Strains of
Nieto Ramirez LM; Quintero Vargas K; Diaz G
Antibiotics (Basel); 2020 Mar; 9(3):. PubMed ID: 32209979
[TBL] [Abstract][Full Text] [Related]
5. Favorable outcome of individual regimens containing bedaquiline and delamanid in drug-resistant tuberculosis: A systematic review.
Putra ON; Yulistiani Y; Soedarsono S; Subay S
Int J Mycobacteriol; 2023; 12(1):1-9. PubMed ID: 36926755
[TBL] [Abstract][Full Text] [Related]
6. Concomitant bedaquiline and delamanid therapy in patients with drug-resistant extra-pulmonary tuberculosis in Mumbai, India.
Mongia H; Mamnoon F; Silsarma A; Mahajan R; Dalal A; Galindo MA; Iyer A; Singh P; Mansoor H; Das M; Morales M; Spencer H; Isaakidis P
J Clin Tuberc Other Mycobact Dis; 2024 May; 35():100433. PubMed ID: 38617837
[TBL] [Abstract][Full Text] [Related]
7. One Step Forward: Successful End-of-Treatment Outcomes of Patients With Drug-Resistant Tuberculosis Who Received Concomitant Bedaquiline and Delamanid in Mumbai, India.
Das M; Dalal A; Laxmeshwar C; Ravi S; Mamnoon F; Meneguim AC; Paryani R; Mathur T; Singh P; Mansoor H; Kalon S; Hossain FN; Lachenal N; Coutisson S; Ferlazzo G; Isaakidis P
Clin Infect Dis; 2021 Nov; 73(9):e3496-e3504. PubMed ID: 33079176
[TBL] [Abstract][Full Text] [Related]
8. New TB drugs for the treatment of children and adolescents with rifampicin-resistant TB in Mumbai, India.
Das M; Mamnoon F; Mansoor H; Meneguim AC; Singh P; Shah I; Ravi S; Kalon S; Hossain FN; Ferlazzo G; Isaakidis P; Furin J; Acharya S; Thakur HP
Int J Tuberc Lung Dis; 2020 Dec; 24(12):1265-1271. PubMed ID: 33317670
[No Abstract] [Full Text] [Related]
9. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study.
Ferlazzo G; Mohr E; Laxmeshwar C; Hewison C; Hughes J; Jonckheere S; Khachatryan N; De Avezedo V; Egazaryan L; Shroufi A; Kalon S; Cox H; Furin J; Isaakidis P
Lancet Infect Dis; 2018 May; 18(5):536-544. PubMed ID: 29452942
[TBL] [Abstract][Full Text] [Related]
10. Injectable-free regimens containing bedaquiline, delamanid, or both for adolescents with rifampicin-resistant tuberculosis in Khayelitsha, South Africa.
Mohr-Holland E; Reuter A; Furin J; Garcia-Prats A; De Azevedo V; Mudaly V; Kock Y; Trivino-Duran L; Isaakidis P; Hughes J
EClinicalMedicine; 2020 Mar; 20():100290. PubMed ID: 32154506
[TBL] [Abstract][Full Text] [Related]
11. Treatment outcomes of children and adolescents receiving drug-resistant TB treatment in a routine TB programme, Mumbai, India.
Dhakulkar S; Das M; Sutar N; Oswal V; Shah D; Ravi S; Vengurlekar D; Chavan V; Rebello L; Meneguim AC; Iyer A; Mansoor H; Kalon S; Acharya S; Ferlazzo G; Isaakidis P; Thakur HP
PLoS One; 2021; 16(2):e0246639. PubMed ID: 33600431
[TBL] [Abstract][Full Text] [Related]
12. Epidemiology and factors associated with Extra-pulmonary tuberculosis in a Low-prevalence area.
Rolo M; González-Blanco B; Reyes CA; Rosillo N; López-Roa P
J Clin Tuberc Other Mycobact Dis; 2023 Aug; 32():100377. PubMed ID: 37252369
[TBL] [Abstract][Full Text] [Related]
13. Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline.
Tanneau L; Karlsson MO; Diacon AH; Shenje J; De Los Rios J; Wiesner L; Upton CM; Dooley KE; Maartens G; Svensson EM
Clin Pharmacokinet; 2022 Aug; 61(8):1177-1185. PubMed ID: 35668346
[TBL] [Abstract][Full Text] [Related]
14. Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort.
Hewison C; Khan U; Bastard M; Lachenal N; Coutisson S; Osso E; Ahmed S; Khan P; Franke MF; Rich ML; Varaine F; Melikyan N; Seung KJ; Adenov M; Adnan S; Danielyan N; Islam S; Janmohamed A; Karakozian H; Kamene Kimenye M; Kirakosyan O; Kholikulov B; Krisnanda A; Kumsa A; Leblanc G; Lecca L; Nkuebe M; Mamsa S; Padayachee S; Thit P; Mitnick CD; Huerga H
Clin Infect Dis; 2022 Sep; 75(6):1006-1013. PubMed ID: 35028659
[TBL] [Abstract][Full Text] [Related]
15. Concurrent use of bedaquiline and delamanid for the treatment of fluoroquinolone-resistant multidrug-resistant tuberculosis: a nationwide cohort study in South Korea.
Kwon YS; Jeon D; Kang H; Yim JJ; Shim TS
Eur Respir J; 2021 Mar; 57(3):. PubMed ID: 33093123
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
